CERUS CORP (CERS)       3.7  -0.16 (-4.15%)

3.7  -0.16 (-4.15%)

US1570851014 - Common Stock - After market: 3.7 0 (0%)

CERUS CORP3.7

NASDAQ:CERS (11/28/2022, 7:00:01 PM)-0.16 (-4.15%)

After market: 3.7 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Health Care Equipment & Supplies
Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend
Overview
Earnings (Last) 11-03 2022-11-03/amc Earnings (Next) 02-20 2023-02-20
Ins Owners 3.28% Inst Owners 82.95%
Market Cap 656.46M Shares 177.42M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 87.27
IPO 01-31 1997-01-31

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CERS Daily chart

Company Profile

Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.

Company Info

CERUS CORP

1220 Concord Ave Ste 600, 2550 Stanwell Drive

Concord CALIFORNIA 94520

P: 19252886000.0

CEO: William M. Greenman

Employees: 294

Website: https://www.cerus.com/

CERS Twits

Here you can normally see the latest stock twits on CERS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example